Welcome to CVD Risk Reduction and Lipid Management: State of the Science in HDL Therapy. This CME-certified initiative is intended for cardiologists and primary care physicians involved in the treatment of patients with dyslipidemia. A series of live CME-certified programs will be presented at selected hospitals throughout the US during 2012 and early 2013. Click on the Calendar of Live Events to see if it is coming to a hospital near you. You can also view this important online program on-demand and receive CME credit. Click on the link below to access the full, online program.
This new program examines the importance of lipoprotein management for secondary prevention of major adverse cardiac events in post-ACS patients. Participants will learn to recognize residual risk associated with even intense statin therapy to lower LDL, as well as the limitations of current therapies to increase HDL, while building an awareness of the prospects of novel therapies to increase HDL and reduce CVD risk in ACS patients, and to provide primary prevention in high-risk patients.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Potomac Center for Medical Education designates this educational activity for a maximum of 1.0 AMA PRA Category I credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
For information about the accreditation of this program, please email email@example.com